Barclays Slightly Lowers Estimates on Nike (NKE); Still Sees Well-Positioned Outlook
Get Alerts NKE Hot Sheet
Price: $40.73 -1.21%
Rating Summary:
26 Buy, 28 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
26 Buy, 28 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Nike (NYSE: NKE) price target maintained at $125.00.
Analyst, Robert S. Drbul, said, "Nike reported 3Q12 EPS of $1.20 yesterday, $0.01 above our estimate and $0.03 above consensus. Revenue rose 15.1% to $5.85 billion, above our 14.2% estimate. We view the sizeable double digit-growth in developed markets, North America (+17.0%) and China (+25.3%), as indicative of ongoing strength of the brand."
"With notable strength in futures, we remain confident in our outlook and are
maintaining our PT of $125. Given cost pressures improving slower than expected, we are lowering our FY12 and FY13 EPS to $4.95 and $5.70 from $5.00 and $5.80."
For an analyst ratings summary and ratings history on Nike click here. For more ratings news on Nike click here.
Shares of Nike closed at $110.99 yesterday.
Analyst, Robert S. Drbul, said, "Nike reported 3Q12 EPS of $1.20 yesterday, $0.01 above our estimate and $0.03 above consensus. Revenue rose 15.1% to $5.85 billion, above our 14.2% estimate. We view the sizeable double digit-growth in developed markets, North America (+17.0%) and China (+25.3%), as indicative of ongoing strength of the brand."
"With notable strength in futures, we remain confident in our outlook and are
maintaining our PT of $125. Given cost pressures improving slower than expected, we are lowering our FY12 and FY13 EPS to $4.95 and $5.70 from $5.00 and $5.80."
For an analyst ratings summary and ratings history on Nike click here. For more ratings news on Nike click here.
Shares of Nike closed at $110.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades BSE Limited (BSE:IN) to Underperform
- JX Advanced Metals (5016:JP) PT Lowered to JPY4,800 at JPMorgan
- Astellas Pharma Inc (4503:JP) (ALPMY) PT Raised to JPY2,500 at JPMorgan
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share